{"id":"placebo-gemigliptin","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL3707235","moleculeType":"Small molecule","molecularWeight":"489.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gemigliptin is a DPP-4 inhibitor that prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby prolonging their action. This leads to increased insulin secretion and decreased glucagon secretion in a glucose-dependent manner, resulting in improved glycemic control. The drug is selective for DPP-4 and has a long half-life allowing once-daily dosing.","oneSentence":"Gemigliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve blood glucose control in type 2 diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:28.398Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03842267","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)","status":"COMPLETED","sponsor":"LG Chem","startDate":"2019-05-13","conditions":"Diabetes Mellitus, Type 2","enrollment":315},{"nctId":"NCT04255238","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2020-06-30","conditions":"Diabetes Mellitus, Type 2","enrollment":468},{"nctId":"NCT02831361","phase":"PHASE3","title":"Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2016-10-17","conditions":"Type 2 Diabetes Mellitus","enrollment":290},{"nctId":"NCT02126358","phase":"PHASE3","title":"Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2014-05","conditions":"Type 2 Diabetes, Dyslipidemia","enrollment":290},{"nctId":"NCT02186080","phase":"NA","title":"Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-07","conditions":"Type 2 Diabetes Mellitus","enrollment":10},{"nctId":"NCT02250872","phase":"PHASE2, PHASE3","title":"Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-12","conditions":"Cancer, Cisplatin Adverse Reaction","enrollment":182},{"nctId":"NCT01990469","phase":"PHASE3","title":"Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2014-01","conditions":"T2DM","enrollment":219},{"nctId":"NCT01968044","phase":"PHASE3","title":"A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2013-10","conditions":"Type 2 DM Patients With Moderate or Severe Renal Impairment","enrollment":132},{"nctId":"NCT01787396","phase":"PHASE3","title":"Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2013-04","conditions":"Type 2 Diabetes Mellitus","enrollment":433},{"nctId":"NCT02089126","phase":"PHASE3","title":"Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"LG Life Sciences","startDate":"2014-06","conditions":"Type 2 Diabetes Mellitus","enrollment":230},{"nctId":"NCT01602003","phase":"PHASE3","title":"Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2009-12","conditions":"Type 2 Diabetes Mellitus","enrollment":425},{"nctId":"NCT01601990","phase":"PHASE3","title":"Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2009-12","conditions":"Type 2 Diabetes Mellitus","enrollment":189}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo(Gemigliptin)","genericName":"Placebo(Gemigliptin)","companyName":"LG Life Sciences","companyId":"lg-life-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemigliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve blood glucose control in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}